FiercePharma 4Oct2019 Article "Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: repor | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  722 of 1243  at  10/11/2019 9:54:17 AM  by

JBWIN


FiercePharma 4Oct2019 Article "Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report"

 

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: 

by Eric Sagonowsky |
Oct 4, 2019 11:07am
 
A GlobalData analysis shows Merck's Keytruda will top industry sales in 2025 with $22.5 billion. (Pixabay)
 

AbbVie’s enjoying industry-leading sales for Humira these days, but by 2025, the drug will fall down the rankings to the No. 6 spot in best-selling meds, according to a new forecast from GlobalData. Meanwhile, the analysts expect Merck’s Keytruda to continue making strides and reach $22.5 billion in 2025 sales, topping the industry.

Of course, the Humira fall is not unexpected for AbbVie, which recently inked a massive buyout of Allergan in order to prepare itself for Humira’s U.S. patent cliff, coming in 2023. But even after numerous biosimilars enter the market, GlobalData analysts believe Humira can retain $10.3 billion in 2025 sales. What's more, 2023 is the year the analysts expect Keytruda to take pharma's sales crown.

Behind Keytruda in GlobalData's 2025 sales forecast are Bristol-Myers Squibb and Pfizer’s Eliquis at $18.7 billion, Celgene’s Revlimid at $12.4 billion, Bristol’s Opdivo at $12 billion and AbbVie and Johnson & Johnson’s Imbruvica at $11.9 billion.

 

The best-selling meds in 2025

GlobalData forecast shows Humira falls of top spot, Keytruda to generate $22.5 billion

 
 

BMS is in the process of buying out Celgene, so that buyout will give the drugmaker three of the top four drugs by estimated 2025 sales, totaling more than $43 billion. Of note, the company splits Eliquis revenues with Pfizer.

Behind Humira, Gilead’s new HIV med Biktarvy captures the No. 7 ranking with $10 billion in 2025 sales. Pfizer’s Ibrance, J&J’s Stelara and Eli Lilly and Boehringer Ingelheim’s Trulicity round out the top 10 with sales of $9 billion, $7.5 billion and $7.2 billion, respectively.

GlobalData’s forecast comes after an EvaluatePharma analysis in June predicted many of the same drugs would top pharma’s sales in 2024. Evalaute’s analysis had the order different, though, as the firm predicted Humira would hold on to the No. 2 spot in that year.

Behind Keytruda and Humira, Evalaute predicted Eliquis, Opdivo and Imbruvica would make up the industry's top five drugs in 2024. Ibrance, Revlimid, Stelara, Bayer and Regeneron’s Eylea and Biktarvy rounded out the top 10 in that forecast.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 16     Views: 224
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
725 Re: FiercePharma 4Oct2019 Article "Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report" moranpicks 3 10/14/2019 1:11:32 PM
757 Re: FiercePharma 4Oct2019 Article "Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report" tocentsworth 0 10/22/2019 10:32:27 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...